Normal Tension Glaucoma: Challenges & Opportunities
Okay, here’s a breakdown of the details from the provided text, organized for clarity:
1. References (Research Articles/presentations)
Sit AJ, et al. Surv Ophthalmol. 2025; doi:j.survophthal.2025.03.003. (https://www.surveyophthalmol.com/article/S0039-6257(25)00052-9/fulltext00052-9/fulltext))
Strohmaier CA, et al. Ophthalmol Glaucoma. 2025; doi: 10.1016/J.Oogla.2024.11.006. (https://www.sciencedirect.com/science/article/abs/pii/S2589419624002138?via%3Dihub)
Wirostko B. QLS-111 Phase 2 study presentation. World Glaucoma Congress 2025; June 25-28, 2025; Honolulu. (Presentation - no direct link provided)
Zhao J, et al. Am J Ophthalmol. 2019; DOI: 10.1016 / J.Act.2018.10.017. (https://www.ajo.com/article/S0002-9394(18)30605-6/abstract30605-6/abstract))
2. Contact Information (Experts)
Michael chaglasian, OD: associate Professor & Chief of Innovative Technology and Data Science, Illinois College of Optometry, Chicago. Email: mchaglas@ico.edu
shan Lin, MD: Research Co-Director, Glaucoma Center of San Francisco. Email: sl@glaucomasf.com
3. Publication Information
Published by: Primary Care Optometry news (logo provided)
4. Disclosures
Michael Chaglasian, OD: Consulting for Alcon, Bausch + lomb, and Topcon Healthcare.
* Shan Lin, MD: scientific advisory board for Qlaris Bio; Speaker/consultant for Santen.
Let me know if you’d like me to focus on a specific aspect of this information or if you have any other questions!